Key clinical point: Outcomes for adult Burkitt lymphoma in a contemporary, large real-world analysis appear inferior to those of smaller published series. Use of rituximab, achievement of initial complete response, and treatment at an academic cancer center were associated with improved survival.

Major finding: Overall, complete response was seen in 72% of patients and partial response in 6%. The treatment-related mortality was 9.3%, with no significant differences seen between patients with and without HIV. With 39-month median follow-up, the 3-year progression-free survival (PFS) and overall survival were 65% and 72%, respectively. Three-year PFS rates were 68% in those treated with rituximab, compared with 39% in those who did not receive rituximab and 68% in patients treated at an academic center versus 45% in those seen at a community cancer center.

Study details: A multi-center retrospective study of 557 newly diagnosed adults with Burkitt lymphoma over a 9-year period (2009-2018).

Disclosures: Dr. Evens reported disclosures related to Seattle Genetics, Pharmacyclics, Epizyme, Tesaro, MorphoSys, Takeda, Merck, and Novartis.